The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
about
Animal models of diabetes mellitus for islet transplantationCasein kinases as potential therapeutic targets.SVMRFE based approach for prediction of most discriminatory gene target for type II diabetes.-NOD Mice Having a Lyn Tyrosine Kinase Mutation Exhibit Abnormal Neutrophil Chemotaxis.LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis.Diabetes Canada 2017.
P2860
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The Lyn kinase activator MLR-1 ...... mal models of type 2 diabetes.
@en
The Lyn kinase activator MLR-1 ...... mal models of type 2 diabetes.
@nl
type
label
The Lyn kinase activator MLR-1 ...... mal models of type 2 diabetes.
@en
The Lyn kinase activator MLR-1 ...... mal models of type 2 diabetes.
@nl
prefLabel
The Lyn kinase activator MLR-1 ...... mal models of type 2 diabetes.
@en
The Lyn kinase activator MLR-1 ...... mal models of type 2 diabetes.
@nl
P2093
P356
P1476
The Lyn kinase activator MLR-1 ...... mal models of type 2 diabetes.
@en
P2093
Alexander R Ochman
Andrew G Reaume
Jeffrey A Handler
P356
10.1124/JPET.112.192187
P407
P577
2012-03-19T00:00:00Z